Hangzhou Yingjian Biological Technology

Hangzhou Yingjian Biological Technology is a clinical-stage biopharmaceutical company focused on the research and development of next-generation immune cell therapies. Based in Hangzhou, China, the company utilizes its proprietary En-T platform to develop Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) therapies for hematological and solid tumors. Its lead candidates, YJ001 and YJ011, target CD19 and BCMA respectively, and are undergoing clinical evaluation for various B-cell malignancies. The company is committed to optimizing cell therapy manufacturing and enhancing the persistence of engineered cells in the tumor microenvironment. Yingjian Biotech aims to provide more effective and affordable cell therapy solutions to patients globally.